A Comparative Study Between Tramadol and Dexmedetomidine as Adjuvant to Bupivacaine Through Ultrasound-Guided Transverse Abdominis Plane (TAP) Block for Postoperative Analgesia in Lower Abdominal Surgery

Full text

Text extracted from the article PDF for reading and search. Tables, figures and equations are in the PDF, which remains the authoritative version.

Introduction

Postoperative pain management remains a critical component of perioperative care, directly influencing patient recovery, satisfaction, and clinical outcomes [1]. Inadequate pain control following lower abdominal surgeries can lead to delayed mobilization, prolonged hospital stays, increased risk of thromboembolic complications, and chronic pain syndromes [2]. Traditional systemic opioid-based analgesia, while effective, is associated with numerous adverse effects including nausea, vomiting, sedation, respiratory depression, and potential for abuse [3]. Regional anesthesia techniques have gained prominence in modern multimodal analgesia protocols, offering superior pain control with reduced opioid consumption and associated side effects [4]. The transverse abdominis plane (TAP) block, first described by Rafi in 2001, has emerged as an effective regional anesthetic technique for providing analgesia following various abdominal surgical procedures [5].

This technique involves the deposition of local anesthetic into the neurovascular plane between the internal oblique and transversus abdominis muscles, thereby blocking the thoracolumbar nerves (T7-L1) that supply the anterolateral abdominal wall [6].

The advent of ultrasound guidance has revolutionized regional anesthesia by enabling real-time visualization of anatomical structures, needle trajectory, and local anesthetic spread, thereby improving block success rates and safety profiles [7]. Ultrasound-guided TAP block has demonstrated efficacy in various surgical procedures including cesarean sections, appendectomies, hernia repairs, and hysterectomies [8,9]. Local anesthetics, particularly bupivacaine, form the cornerstone of TAP blocks due to their long duration of action and favorable safety profile [10]. However, the analgesic duration of bupivacaine alone may be insufficient for optimal postoperative pain management, typically lasting 6-8 hours [11]. This limitation has prompted investigation into various adjuvants that can prolong the duration and enhance the quality of regional anesthesia [12]. Tramadol, a centrally acting synthetic opioid analgesic with dual mechanisms of action (μ-opioid receptor agonism and monoamine reuptake inhibition), has been explored as an adjuvant in regional anesthesia [13]. Studies have suggested that tramadol may prolong the duration of peripheral nerve blocks through both local anesthetic-like properties and central mechanisms [14]. Its relatively favorable side effect profile compared to traditional opioids makes it an attractive option for peripheral administration [15]. Dexmedetomidine, a highly selective α2-adrenoreceptor agonist with sedative, analgesic, and sympatholytic properties, has garnered significant attention as a neuraxial and peripheral nerve block adjuvant [16]. Its mechanism involves hyperpolarization of nerve fibers through activation of α2-adrenoreceptors on peripheral nerves, resulting in prolonged sensory and motor blockade [17]. Multiple studies have documented dexmedetomidine's ability to significantly extend the duration of various regional anesthetic techniques without significant adverse effects [18,19]. Despite growing evidence supporting the use of adjuvants in TAP blocks, there remains limited comparative data specifically evaluating tramadol versus dexmedetomidine in this context. Most existing studies have compared these agents individually against plain local anesthetic solutions or examined their use in different regional techniques [20,21]. A direct comparison in ultrasound-guided TAP blocks for lower abdominal surgeries would provide valuable clinical guidance for optimizing postoperative analgesia protocols. Lower abdominal surgeries encompass a wide spectrum of procedures including gynecological operations, urological interventions, and general surgical procedures below the umbilicus. These operations typically result in moderate to severe postoperative pain, making them ideal candidates for TAP block analgesia [22]. The effectiveness of TAP blocks in this surgical population has been well-established, but optimization through adjuvant selection remains an area requiring further investigation [23].

This study was designed to conduct a comprehensive comparison between tramadol and dexmedetomidine as adjuvants to bupivacaine in ultrasound-guided TAP blocks for patients undergoing lower abdominal surgeries. We hypothesized that dexmedetomidine would provide superior analgesia duration and quality compared to tramadol, based on its pharmacological properties and emerging evidence from other regional anesthesia applications. The primary objective was to compare the duration of postoperative analgesia, while secondary objectives included assessment of pain intensity scores, rescue analgesic requirements, hemodynamic stability, and incidence of adverse effects.

Methodology

Study Design and Ethical Considerations This prospective, randomized, double-blind, controlled clinical trial was conducted at the Department of Anesthesiology from January 2023 to December 2023. The study protocol was approved by the Institutional Ethics Committee (approval number: IEC/2022/567) and registered with the Clinical Trials Registry (CTRI/2023/01/039456). Written informed consent was obtained from all participants after detailed explanation of the study procedures, potential risks, and benefits. The study adhered to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.

Sample Size Calculation Sample size was calculated based on a pilot study comparing duration of analgesia between groups. Assuming an effect size of 1.2 hours difference in mean duration of analgesia with a standard deviation of 1.5 hours, power of 80%, and alpha error of 0.05, a minimum of 25 patients per group was required. Accounting for a potential 20% dropout rate, we enrolled 30 patients in each group, yielding a total sample size of 90 patients.

Patient Selection Inclusion Criteria • Age 18-65 years • American Society of Anesthesiologists (ASA) physical status I-II • Scheduled for elective lower abdominal surgery under general anesthesia • Body Mass Index (BMI) 18-30 kg/m² • Written informed consent Exclusion Criteria • Patient refusal • Known hypersensitivity to study drugs • Local infection at injection site • Coagulopathy or anticoagulant therapy • Chronic pain conditions or opioid dependence • Psychiatric disorders • Hepatic or renal dysfunction • Pregnancy or lactation • Communication barriers Randomization and Blinding Patients were randomly allocated into three groups using computer-generated random numbers sealed in opaque envelopes. Group allocation was: • Group B (n=30): Bupivacaine 0.25% (20 ml) + Normal saline (2 ml) • Group BT (n=30): Bupivacaine 0.25% (20 ml) + Tramadol 100 mg (2 ml)

Study drugs were prepared by an anesthesiologist not involved in patient care or data collection. All solutions were prepared to a total volume of 22 ml. Patients, surgeons, anesthesiologists performing the block, and data collectors were blinded to group allocation.

Anesthetic Management All patients underwent standardized preoperative assessment including detailed history, physical examination, and routine investigations. Patients were kept nil per oral for 6-8 hours preoperatively. On arrival to the operating room, standard ASA monitoring was established including electrocardiography, non-invasive blood pressure, pulse oximetry, capnography, and temperature monitoring. Premedication consisted of intravenous midazolam 0.03 mg/kg and fentanyl 2 μg/kg. General anesthesia was induced with propofol 2 mg/kg and maintained with sevoflurane (1- 2% end-tidal concentration) in oxygen-air mixture. Neuromuscular blockade was achieved with atracurium 0.5 mg/kg, and tracheal intubation was performed. Intraoperative analgesia was supplemented with fentanyl boluses as needed. All patients received standardized intraoperative fluid management and monitoring.

Ultrasound-Guided TAP Block Technique Bilateral ultrasound-guided TAP blocks were performed at the end of surgery before emergence from general anesthesia. The procedure was conducted using a high-frequency (10-15 MHz) linear ultrasound probe (SonoSite M-Turbo, USA) under strict aseptic conditions.

1. Patient positioned supine with arms abducted

2. Probe placed transversely on the anterior axillary line between the iliac crest and costal margin 3. Three muscle layers identified: external oblique, internal oblique, and transversus abdominis 4. A 22-gauge, 80-mm block needle inserted in-plane from anteromedial to posterolateral direction 5. Needle tip advanced into the fascial plane between internal oblique and transversus abdominis muscles 6. After negative aspiration, 1-2 ml test dose administered to confirm correct placement 7. Study drug solution (11 ml) injected on each side under direct ultrasound visualization 8. Adequate spread of local anesthetic confirmed by hypoechoic shadow separating muscle layers The procedure was performed by experienced anesthesiologists (>2 years experience in ultrasound-guided regional anesthesia, >50 previous TAP blocks). Block performance time and any procedural complications were recorded.

Postoperative Management and Monitoring Following surgery, patients were monitored in the post-anesthesia care unit (PACU) for 2 hours before transfer to the surgical ward. Standard postoperative monitoring included vital signs assessment every 15 minutes for the first hour, then hourly for 24 hours.

Rescue Analgesia Protocol: Patients received intravenous paracetamol 1 gram every 6 hours as baseline analgesia. Rescue analgesia (intravenous tramadol 50 mg) was administered when Visual Analog Scale (VAS) score ≥4 or upon patient request. Additional doses could be given with minimum 6-hour intervals if needed.

Outcome Measures Primary Outcomes

1. Duration of Analgesia: Time from TAP block

completion to first rescue analgesic request (hours) 2. Pain Scores: VAS scores (0-10 scale, 0=no pain, 10=worst imaginable pain) recorded at 0, 2, 4, 6, 8, 12, 18, and 24 hours postoperatively at rest and during movement

3. Rescue Analgesic Requirement: Total number of

patients requiring rescue analgesia and total rescue analgesic consumption in first 24 hours Secondary Outcomes

1. Hemodynamic Parameters: Heart rate (HR), systolic

blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and peripheral oxygen saturation (SpO₂) recorded at baseline, 0, 2, 4, 6, 12, 18, and 24 hours postoperatively

2. Sedation Score: Ramsay Sedation Scale

(1=anxious/agitated, 2=cooperative/oriented, 3=responds to commands, 4=brisk response to stimulation, 5=sluggish response, 6=no response) assessed at same time intervals 3. Adverse Effects: Nausea, vomiting, pruritus, sedation, respiratory depression, hypotension, bradycardia, urinary retention, and any other complications documented 4. Patient Satisfaction: Assessed at 24 hours using a 5- point Likert scale (1=very dissatisfied, 5=very satisfied)

Statistical Analysis Data were analyzed using SPSS version 25.0 (IBM Corp., Armonk, NY). Normal distribution was assessed using the Kolmogorov-Smirnov test. Continuous variables with normal distribution were expressed as mean ± standard deviation and compared using one-way ANOVA followed by post-hoc Tukey's test. Non-normally distributed data were expressed as median (interquartile range) and analyzed using Kruskal-Wallis test. Categorical variables were presented as frequencies and percentages, and compared using Chi-square test or Fisher's exact test as appropriate. Repeated measures ANOVA was used for comparing parameters at multiple time points. A p-value <0.05 was considered statistically significant. Intention-to-treat analysis was performed for all enrolled patients.

Results

Patient Demographics and Baseline Characteristics A total of 95 patients were initially assessed for eligibility. Five patients were excluded (3 declined participation, 2 did not meet inclusion criteria). Ninety patients were randomized and completed the study without dropouts. Demographic and clinical characteristics were comparable among the three groups with no statistically significant differences (Table 1).

Visual Analog Scale Scores VAS scores at rest and during movement showed significant intergroup differences at all postoperative time points (Table 3). Group BD consistently demonstrated the lowest pain scores, followed by Group BT and Group B. The difference was most pronounced during the 4-12 hour postoperative period.

Fig 1: Mean VAS Scores at Rest Over 24 Hours Rescue Analgesic Requirements All patients in Group B, 28 patients (93.3%) in Group BT, and 22 patients (73.3%) in Group BD required rescue analgesia within 24 hours (p=0.006). Total rescue analgesic consumption was significantly lower in Group BD compared to other groups (p<0.001).

Secondary Outcomes Hemodynamic Parameters Baseline hemodynamic parameters were comparable among groups. Throughout the 24-hour observation period, all groups maintained stable hemodynamics without clinically significant differences in heart rate, blood pressure, or oxygen saturation (Table 4). No patient experienced severe hypotension (MAP <60 mmHg) or bradycardia (HR <50 bpm) requiring intervention.

Adverse Effects The incidence of adverse effects was low across all groups (Table 5). Nausea and vomiting were the most common complications, with no significant intergroup differences. One patient in Group BD experienced mild bradycardia (HR 52 bpm) that resolved spontaneously without intervention. No serious adverse events occurred in any group.

Fig 3: Patient Satisfaction Scores Fig 4: Percentage of Patients Requiring Rescue Analgesia

Discussion

This prospective, randomized, double-blind study provides compelling evidence that both tramadol and dexmedetomidine, when used as adjuvants to bupivacaine in ultrasound-guided TAP blocks, significantly enhance postoperative analgesia following lower abdominal surgeries. Importantly, our findings demonstrate that dexmedetomidine offers superior analgesic efficacy compared to tramadol, with longer duration of analgesia, lower pain scores, reduced rescue analgesic requirements, and higher patient satisfaction, while maintaining an excellent safety profile.

Duration and Quality of Analgesia The most striking finding of our study was the significantly prolonged duration of analgesia in the dexmedetomidine group (18.4 ± 2.3 hours) compared to tramadol (12.6 ± 1.8 hours) and plain bupivacaine (8.2 ± 1.5 hours). This represents a 124% increase over plain bupivacaine and a 46% increase over tramadol. These results align with previous research demonstrating dexmedetomidine's ability to prolong peripheral nerve blocks [24]. Marhofer et al. reported similar findings in their study of TAP blocks, noting duration increases of approximately 40-60% with dexmedetomidine adjuvant [25].

The mechanism underlying dexmedetomidine's prolongation effect appears multifactorial. Alpha-2 adrenoreceptor activation on peripheral nerves leads to hyperpolarization through G-protein-coupled potassium channel opening, thereby reducing neuronal excitability [26]. Additionally, dexmedetomidine may exert local vasoconstrictor effects, reducing local anesthetic absorption and prolonging its presence at the site of action [27]. Some studies have also suggested anti-inflammatory and analgesic effects mediated through central and peripheral α2-receptors [28]. Our tramadol group demonstrated moderate prolongation of analgesia (54% increase over plain bupivacaine), consistent with findings by Goyal et al., who reported similar benefits when tramadol was added to bupivacaine in TAP blocks [29]. Tramadol's peripheral analgesic effects may result from local anesthetic-like sodium channel blockade, local anti-inflammatory action, and possibly central uptake producing systemic analgesia [30]. However, the exact mechanisms remain incompletely understood, and the clinical benefit appears less pronounced than with dexmedetomidine.

Pain Scores and Rescue Analgesia VAS scores demonstrated significant differences among groups, particularly during the critical 4-12 hour postoperative period. The dexmedetomidine group maintained lower pain scores throughout the observation period, translating to improved patient comfort and reduced analgesic requirements. This finding is clinically significant as it suggests not merely prolonged duration but also enhanced quality of analgesia.

The reduction in rescue analgesic consumption in the dexmedetomidine group (57% reduction compared to control) has important implications for opioid-sparing analgesia strategies. In the current era emphasizing multimodal analgesia and opioid stewardship, techniques that effectively reduce systemic opioid requirements are particularly valuable [31]. Our results support the integration of dexmedetomidine-enhanced TAP blocks into enhanced recovery after surgery (ERAS) protocols for lower abdominal procedures.

Interestingly, 73.3% of patients in the dexmedetomidine group still required some rescue analgesia within 24 hours, indicating that even optimized TAP blocks should be considered as part of a comprehensive multimodal analgesic strategy rather than standalone treatment. This underscores the importance of combining regional techniques with appropriate systemic analgesia, as recommended by current pain management guidelines [32].

Hemodynamic Stability Our study demonstrated excellent hemodynamic stability across all groups, with no clinically significant differences in heart rate, blood pressure, or oxygen saturation. This finding is reassuring given theoretical concerns about systemic absorption of adjuvants, particularly dexmedetomidine, which can cause bradycardia and hypotension when administered systemically [33].

The doses of adjuvants used in our study (tramadol 100 mg, dexmedetomidine 1 μg/kg) are well below systemic therapeutic doses and appear to exert predominantly local effects when administered in the TAP plane. Esmaoglu et al. similarly reported minimal systemic effects with perineural dexmedetomidine [34]. The single case of mild bradycardia in our dexmedetomidine group resolved spontaneously and required no intervention, suggesting that clinically significant systemic effects are rare at these doses. The stable hemodynamics observed in our study are particularly relevant for elderly patients and those with cardiovascular comorbidities, populations commonly requiring lower abdominal surgery. The safety profile demonstrated here supports the broader applicability of these techniques across diverse patient populations.

Safety Profile and Adverse Effects The low incidence of adverse effects across all groups is noteworthy and compares favorably with systemic opioid-based analgesia regimens [35]. The absence of respiratory depression in any patient is particularly significant, as respiratory complications represent a major concern with opioid analgesia. The similar rates of nausea and vomiting across groups suggest these symptoms were primarily related to surgical factors and general anesthesia rather than the TAP block adjuvants [36].

The minimal sedation observed in the dexmedetomidine group, while statistically significant, remained within clinically acceptable ranges with all patients easily arousable. This mild sedation might actually be beneficial during the early postoperative period, potentially contributing to patient comfort without compromising safety or recovery [37].

Comparison with Existing Literature Our findings are consistent with the growing body of evidence supporting dexmedetomidine as a superior adjuvant in regional anesthesia. Abdallah et al.'s meta-analysis of perineural dexmedetomidine demonstrated significant prolongation of sensory and motor blockade across various peripheral nerve blocks [38]. Similarly, a systematic review by Ping et al. specifically examining TAP blocks found dexmedetomidine to be highly effective in extending analgesia duration [39].

Studies comparing tramadol and dexmedetomidine in other regional anesthesia contexts have generally favored dexmedetomidine. Kaur et al. compared these adjuvants in supraclavicular brachial plexus blocks and reported findings similar to ours, with dexmedetomidine providing longer analgesia [40]. However, direct comparisons in TAP blocks specifically remain limited, making our study a valuable addition to the literature.

The dose of dexmedetomidine used in our study (1 μg/kg) falls within the commonly studied range (0.5-1.5 μg/kg). Some studies have suggested that lower doses (0.5 μg/kg) may provide comparable efficacy with potentially fewer side effects [41], while others have found dose-dependent benefits up to 1.5 μg/kg [42]. Future dose-ranging studies in TAP blocks would help optimize the risk-benefit ratio.

Clinical Implications The superior performance of dexmedetomidine in our study has several important clinical implications. First, it provides evidence-based guidance for selecting adjuvants when enhanced postoperative analgesia is desired. The nearly 10- hour additional analgesia compared to tramadol could substantially impact patient recovery trajectories, potentially facilitating earlier mobilization, shorter hospital stays, and reduced overall healthcare costs.

Second, the opioid-sparing effects of dexmedetomidine-enhanced TAP blocks align well with current initiatives to reduce opioid consumption and associated adverse effects. In the context of the ongoing opioid crisis and increasing awareness of opioid-related complications, regional anesthesia techniques that effectively minimize opioid requirements are particularly valuable [43]. Third, the excellent safety profile observed supports the incorporation of dexmedetomidine-enhanced TAP blocks into routine clinical practice for lower abdominal surgeries. The technique appears suitable for a broad patient population and could be integrated into standardized analgesia protocols.

Ultrasound Guidance Considerations The use of ultrasound guidance in our study represents current best practice in regional anesthesia [44]. Real-time visualization enabled precise drug delivery into the TAP plane, likely contributing to the high success rates observed. The ultrasound-guided approach has been shown to improve block efficacy, reduce local anesthetic volumes required, and minimize complications compared to landmark-based techniques [45].

The learning curve for ultrasound-guided TAP blocks is relatively favorable compared to more complex regional techniques, making this an accessible option for anesthesiologists with basic ultrasound skills. However, adequate training and experience remain essential for optimal outcomes, as evidenced by our inclusion criterion requiring operators to have performed at least 50 previous TAP blocks.

Study Limitations Several limitations of our study warrant consideration. First, we studied a relatively homogeneous patient population (ASA I-II, BMI 18-30 kg/m²) undergoing elective surgery. Generalizability to higher-risk patients, emergency procedures, or those with significant comorbidities requires further investigation. Second, we followed patients for only 24 hours postoperatively. Extended follow-up would provide valuable information about subsequent pain trajectories, opioid consumption, functional recovery, and potential development of chronic pain.

Third, we did not measure plasma concentrations of adjuvants to confirm predominantly local versus systemic effects. While our hemodynamic data suggest minimal systemic absorption, pharmacokinetic studies would provide more definitive evidence. Fourth, we did not assess cost-effectiveness, which is an important consideration for healthcare systems evaluating adoption of adjuvant strategies.

Fifth, our study compared bilateral TAP blocks, which may limit applicability to unilateral procedures. However, most lower abdominal surgeries involve bilateral pain, making bilateral blocks clinically appropriate. Finally, we did not include objective measures of functional recovery such as time to ambulation, return of bowel function, or quality of recovery scores, which would have provided additional outcome data.

Future Research Directions Future studies should address several important questions. Comparative effectiveness research examining different dexmedetomidine doses in TAP blocks would help optimize dosing strategies. Investigation of combination adjuvants (e.g., dexmedetomidine plus dexamethasone) might reveal synergistic effects [46]. Studies in specific surgical populations (e.g., cesarean section, major gynecological surgery) would provide procedure-specific guidance.

Long-term outcome studies examining the impact of enhanced acute pain control on chronic pain development, functional recovery, and patient-reported outcomes would be valuable. Economic analyses evaluating cost-effectiveness from healthcare system and societal perspectives would inform policy decisions. Finally, investigation of predictors of response to adjuvant-enhanced TAP blocks could enable personalized analgesic strategies.

Mechanistic Considerations While our study focused on clinical outcomes, the mechanisms underlying adjuvant effects deserve consideration. The superior performance of dexmedetomidine likely reflects its multifaceted mechanisms of action. Beyond α2-adrenoreceptor-mediated effects, dexmedetomidine may modulate inflammatory responses in surgical tissues [47]. Surgical trauma triggers local inflammatory cascades involving prostaglandins, cytokines, and other mediators that contribute to postoperative pain. Dexmedetomidine's potential anti-inflammatory properties could complement its direct neural effects. Tramadol's mechanisms in peripheral nerve blocks remain less well characterized. Beyond its weak opioid receptor activity and monoamine reuptake inhibition, tramadol may possess local anesthetic-like properties through sodium channel blockade [48]. However, the relative contributions of local versus systemic effects remain uncertain. Some researchers have questioned whether tramadol's benefits in peripheral nerve blocks result primarily from systemic absorption rather than local action [49]. The differential performance of tramadol and dexmedetomidine in our study suggests that their mechanisms of prolonging local anesthetic action differ substantially. This observation supports the hypothesis that dexmedetomidine exerts more potent local effects on nerve conduction and local anesthetic pharmacokinetics compared to tramadol.

Safety Monitoring and Risk Mitigation While our study demonstrated excellent safety profiles for both adjuvants, appropriate patient selection and monitoring remain essential. Patients with significant cardiovascular disease, particularly those with bradyarrhythmias or heart block, may require additional caution when considering dexmedetomidine. Pre-existing liver or kidney dysfunction could affect drug metabolism and elimination, potentially increasing risk of adverse effects.

Standardized monitoring protocols should include regular assessment of vital signs, sedation level, and pain scores during the postoperative period. Staff should be educated about potential adverse effects and appropriate responses.

Clear protocols for managing complications such as excessive sedation, bradycardia, or hypotension should be established.

The rare occurrence of adverse effects in our study should not lead to complacency. Vigilant monitoring and preparedness for managing potential complications remain essential components of safe practice. The excellent safety profile observed reflects both the inherent safety of these techniques when properly performed and the careful patient selection and monitoring employed in our study.

Conclusion

This prospective, randomized, double-blind study demonstrates that both tramadol and dexmedetomidine significantly enhance the efficacy of bupivacaine in ultrasound-guided transverse abdominis plane blocks for postoperative analgesia following lower abdominal surgery. Dexmedetomidine emerged as the superior adjuvant, providing substantially longer duration of analgesia (18.4 hours versus 12.6 hours with tramadol and 8.2 hours with plain bupivacaine), lower pain scores, reduced rescue analgesic requirements, and higher patient satisfaction scores.

The excellent safety profile observed with both adjuvants, characterized by stable hemodynamics and minimal adverse effects, supports their clinical utility. The significant opioid-sparing effects, particularly with dexmedetomidine, align well with contemporary multimodal analgesia strategies and enhanced recovery protocols.

Based on these findings, we recommend dexmedetomidine (1 μg/kg) as the preferred adjuvant to bupivacaine for ultrasound-guided TAP blocks in patients undergoing lower abdominal surgery. This approach provides superior postoperative analgesia, reduces opioid consumption, and maintains an excellent safety profile. Tramadol represents a reasonable alternative when dexmedetomidine is unavailable or contraindicated, offering moderate enhancement over plain bupivacaine.

Integration of adjuvant-enhanced TAP blocks into multimodal analgesia protocols can significantly improve postoperative pain management, potentially facilitating enhanced recovery, earlier hospital discharge, and improved patient outcomes. Future research should focus on dose optimization, long-term outcomes, cost-effectiveness analysis, and identification of patient populations most likely to benefit from these techniques.

The findings of this study contribute to the growing evidence base supporting the use of peripheral nerve block adjuvants and provide practical guidance for clinicians seeking to optimize postoperative analgesia while minimizing opioid-related complications. As regional anesthesia techniques continue to evolve, ultrasound-guided TAP blocks with appropriate adjuvants represent a valuable tool in the modern anesthesiologist's armamentarium for managing postoperative pain.